EGFR and non-small cell lung carcinoma: Considering the development of targeted therapies, the National Comprehensive Cancer Network (NCCN) recommends that all patients with metastatic non-squamous NSCLC undergo biomarker testing for oncogenic drivers including ALK rearrangements, BRAF mutations, EGFR mutations, HER2 mutations, and ROS1 rearrangement.